NEW CONCEPTS IN DRUG DISCOVERY AND DEVELOPMENT

Stopping and Reversing Disease Progression

Learn More
WE ARE ENDECE

ENDECE, LLC is a privately held biopharmaceutical company at the forefront of new drug discovery and development. Our library of proprietary compounds, invented and owned by ENDECE, was designed to stop disease by up-regulating specific biological pathways to stimulate a specific biological response. We focus on diseases whose treatment options are limited or non-existent and whose causes may not be well understood including demyelinating diseases such as, neuromyelitis optica spectrum disorder (NMOSD), multiple sclerosis (MS), osmotic demyelination syndrome (ODS), and Alzheimer’s disease (cognition).

ENDECE was founded in 2006 and is located in Mequon, Wisconsin.

Learn More

LATEST NEWS

View All

ENDECE is preparing to take NDC-1308 into clinical studies. Our scientists describe the dual mechanism of action that allows NDC-1308 to induce remyelination for treating diseases such as neuromyelitis optica spectrum disorder (NMOSD), multiple sclerosis (MS), and Alzheimer’s disease.

LEARN HOW ENDECE DISCOVERED NDC-1308 A COMPOUND WITH THE POTENTIAL TO REVOLUTIONIZE THE TREATMENT OF DEMYELINATING DISEASES INCLUDING MS, NMOSD AND ODS.

Learn More

A SMALL MOLECULE INDUCES OLIGODENDROGENESIS LEADING TO MYELIN SHEATH REPAIR